

## N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Danishefsky et al.

Examiner:

S. Ungar

ECH CENTER 1600/2900

Serial No.:

09/833,327

Group Art Unit:

1642

Filed:

April 12, 2001

For:

COLON CANCER KH-1 AND N3 ANTIGENS

Assistant Commissioner for Patents Washington, DC 20231

Sir:

### AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

This Amendment and Response to Restriction Requirement is submitted in response to the Office Action mailed on June 5, 2002 for the above-identified application. The deadline for response to the Office Action is July 5, 2002, and thus Applicant respectfully submits that the filing of this response on July 3, 2002 is timely.

### 1) Response to Restriction Requirement:

As set forth in the Office Action, restriction to one of Groups I, II, III, IV, V, VI, VII, VIII or IX is required. Applicant has canceled all of the pending claims in the present application thereby obviating the Restriction Requirement. As detailed below, Applicant has added claims to the inventive KH-1 carbohydrate constructs, derivatives thereof and pharmaceutical compositions thereof. Thus, Applicant respectfully submits that a Restriction is not required. However, Applicant explicitly reserves the right to pursue any or all of the claims in Groups I, II, III, IV, V, VI, VII, VIII and/or IX in continuation or divisional applications.

# 2) Amendments to the specification:

Applicant respectfully requests entry of the following amendments in the above-referenced application:

#### 1. Please replace the structure: